^
BIOMARKER:

TMB-L

i
Other names: TMB | Tumor Mutational Burden
Related biomarkers:
TMB-L
Melanoma
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
TMB-L
CRC
durvalumab + CP-675206
Sensitive: C3 – Early Trials
TMB-L
Adrenal Cortex Carcinoma
mitotane
Sensitive: C3 – Early Trials
TMB-L
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
TMB-L
Malignant Pleural Mesothelioma
PD-L1 inhibitor
Resistant: C3 – Early Trials
TMB-L
GBM
PD1 inhibitor
Sensitive: C3 – Early Trials
TMB-L
NSCLC
atezolizumab
Sensitive: C3 – Early Trials
TMB-L
NSCLC
durvalumab + CP-675206
Resistant: C3 – Early Trials
TMB-L
Pancreatic Cancer
nivolumab + BMS-986227
Sensitive: C3 – Early Trials
TMB-L
Lung Cancer
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
TMB-L
Gastric Cancer
Immunotherapy
Resistant: C3 – Early Trials
TMB-L
Mast Cell Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
TMB-L
Diffuse Large B Cell Lymphoma
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
TMB-L
NSCLC
nivolumab + HS-110
Sensitive: C3 – Early Trials
TMB-L
Neuroendocrine Tumor
toripalimab
Sensitive: C3 – Early Trials
TMB-L
Pancreatic Ductal Adenocarcinoma
trametinib + Torin1
Sensitive: D – Preclinical
TMB-L
Gastric Cancer
olaparib
Resistant: D – Preclinical